The integration provides Thermo Fisher's customers with a comprehensive suite of metagenomic analysis and microbial profiling tools.
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
The real-time PCR test was developed by Thermo Fisher Scientific and validated by Aeon, and detects 34 different pathogens from vaginal swabs.
The research team evaluated the Illumina MiSeq and Ion PGM sequencing platforms, as well as the bioinformatics pipelines TBProfiler and Mykrobe predictor.
The firm is developing a sepsis and SIRS diagnostic that combines its own molecule counting technology with Thermo Fisher's procalcitonin assay.
The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.
Thermo Fisher said the deal strengthens its portfolio for stem cell research, and it will fold MTI-GlobalStem into its life sciences solutions segment.
Thermo Fisher developed the NGS-based multi-marker assay in collaboration with Novartis and Pfizer to match lung cancer patients with targeted drugs.
Clinical MDx firm OmniSeq has been an early-access user of the research-use-only assay and is working on validating it to predict checkpoint inhibitor response.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.